Kineta rises on positive data from early-stage cancer trial
03/10/2023 15:04
** Shares of drug developer Kineta KA.O rise 6.5% to $4.74
** Co says its experimental therapy KVA12123 showed positive
data in an early-stage trial for advanced solid tumors
** Says it anticipates clinical efficacy data in Q4 2023
** Including session moves, shares down 19.4% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Recent news on Kineta
See all newsBrief: TuHURA Biosciences And Kineta Stockholders Approve Proposed Merger And All Related Proposals
Brief: Kineta Updates KVA12123 Clinical Results From Ongoing Phase 1/2 Vista101 Study At Society For Immunotherapy Of Cancer
U.S. STOCKS ON THE MOVE-Copper miners, Palo Alto Networks, Lowe's
U.S. STOCKS ON THE MOVE-Lineage, J.B. Hunt, McDonald's
Kineta rises on resuming enrollment in early-stage cancer study